UPDATE: Bristol Myers Announces Phase 3 First-Line Study of Nivolumab Stopped Early, Showed Superior Overall Survival vs Davarbazine
June 24, 2014 at 16:46 PM EDT
Bristol-Myers Squibb Company (NYSE: BMY) today announced that a randomized blinded comparative Phase 3 study evaluating nivolumab versus ...